Antigen Presentation to Celiac Lesion-Derived T Cells of a 33-Mer Gliadin Peptide Naturally Formed by Gastrointestinal Digestion

Shuo-Wang Qiao, Elin Bergseng, Øyvind Molberg, Jiang Xia, Burkhard Fleckenstein, Chaitan Khosla and Ludvig M. Sollid

*J Immunol* 2004; 173:1757-1762; doi: 10.4049/jimmunol.173.3.1757
http://www.jimmunol.org/content/173/3/1757

---

Why The JI?

- **Rapid Reviews!** 30 days* from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Speedy Publication!** 4 weeks from acceptance to publication

*average

---

**References**

This article *cites 34 articles*, 17 of which you can access for free at:
http://www.jimmunol.org/content/173/3/1757.full#ref-list-1

**Subscription**

Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

**Permissions**

Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**

Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts

The *Journal of Immunology* is published twice each month by
The American Association of Immunologists, Inc.,
1451 Rockville Pike, Suite 650, Rockville, MD 20852
Copyright © 2004 by The American Association of
Immunologists All rights reserved.
Print ISSN: 0022-1767 Online ISSN: 1550-6606.
Antigen Presentation to Celiac Lesion-Derived T Cells of a 33-Mer Gliadin Peptide Naturally Formed by Gastrointestinal Digestion

Shuo-Wang Qiao, Elin Bergseng, Øyvind Molberg, Jiang Xia, Burkhard Fleckenstein, Chaitan Khosla, and Ludvig M. Sollid

Celiac disease is an HLA-DQ2-associated disorder characterized by intestinal T cell responses to ingested wheat gluten proteins. A peptide fragment of 33 residues (\(\alpha_2\)-gliadin 56–88) produced by normal gastrointestinal proteolysis contains six partly overlapping copies of three T cell epitopes and is a remarkably potent T cell stimulator after deamidation by tissue transglutaminase (TG2). This 33-mer is rich in proline residues and adopts the type II polyproline helical conformation in solution. In this study we report that after deamidation, the 33-mer bound with higher affinity to DQ2 compared with other monovalent peptides harboring gliadin epitopes. We found that the TG2-treated 33-mer was presented equally effectively by live and glutaraldehyde-fixed, EBV-transformed B cells. The TG2-treated 33-mer was also effectively presented by glutaraldehyde-fixed dendritic cells, albeit live dendritic cells were the most effective APCs. A strikingly increased T cell stimulatory potency of the 33-mer compared with a 12-mer peptide was also seen with fixed APCs. The 33-mer showed binding maximum to DQ2 at pH 6.3, higher than maxima found for other high affinity DQ2 binders. The 33-mer is thus a potent T cell stimulator that does not require further processing within APC for T cell presentation and that binds to DQ2 with a pH profile that promotes extracellular binding. *The Journal of Immunology*, 2004, 173: 1757–1762.

Celiac disease is a chronic inflammatory disease of the small intestine caused by the ingestion of proline- and glutamine-rich wheat gluten (consisting of the gliadin and glutenin subcomponents) or related proteins from rye and barley. The lesion is characterized by villous atrophy, crypt hyperplasia, and increased number of infiltrating lymphocytes in both epithelium and lamina propria. Celiac disease has a strong HLA association; \(\sim 90\)% of the patients are HLA-DQ2, and the majority of the remaining patients are HLA-DQ8 (1). Gluten-reactive CD4\(^+\) T cells can be readily isolated from the small intestine of celiac disease patients, but not of controls, and such gluten-reactive T cells are exclusively restricted by the disease-associated DQ2 or DQ8 HLA molecules. The activation of gluten-reactive T cells probably represents a key event in disease development. Gluten-reactive T cells from celiac lesions predominantly recognize gluten peptides in which glutamine residues at certain positions have been converted to glutamic acid by tissue transglutaminase (TG2)\(^2\)-mediated deamidation (1). The negative charges introduced by TG2 generally increase the binding affinity of the gluten peptides to DQ2 (2, 3).

Several different celiac T cell epitopes derived from gliadin proteins have been identified during the last few years (2, 4–7), and these epitopes cluster in the proline-rich regions of the proteins (5). The epitopes identified in \(\alpha\)-gliadins appear to be particularly important because they are recognized by intestinal T cells of the majority of adult celiac patients (2). By mimicking the enzymatic gastrointestinal digestion of a representative \(\alpha\)-gliadin (\(\alpha_2\)-gliadin), Shan and coworkers (8) found a 33-mer (LQLQPFPQPQLPPQPQQSFP) to be particularly interesting. This fragment was resistant to further breakdown by luminal proteases and intestinal brush-border enzymes due to its high proline content (13 of 33 residues are proline). Moreover, it showed strong type II polyproline helical conformation in solution; the same conformation that is adopted by peptides bound to MHC class II molecules (9). The 33-mer contains six partly overlapping copies of three DQ2-restricted T cell \(\alpha\) epitopes (Fig. 1), and the deamidated 33-mer was found to be an extremely potent T cell stimulator, several-fold more potent than any other known gluten peptide (8). Given the fact that this highly immunostimulatory peptide is an end product of the gastrointestinal proteolytic digestion and given its central role in the pathogenesis of celiac disease, we aimed to characterize its binding to the disease-associated DQ2 molecule and the mechanism of its presentation to T cells.

### Materials and Methods

**Peptide synthesis, gliadin protein Ag, and GST-TG2 production**

The \(\gamma\)l peptides YQQLPQEPQOSFPEGEPF (\(\gamma\)-gliadin(Y134–153)E140E148E150, SWISSPROT GDB2_WHEAT) and QPEQQQSF

---

\(^{1}\) Institute of Immunology, Rikshospitalet University Hospital, University of Oslo, Oslo, Norway; and \(^{1}\) Department of Chemistry, Stanford University, Stanford, CA 94305

Received for publication March 9, 2004. Accepted for publication May 19, 2004.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

\(^{1}\) This work was supported by grants from the Research Council of Norway, the European Commission (QLK1–2000–00657), Rikshospitalet University Hospital, the Deutsche Forschungsgemeinschaft (SFB 510, Project D4), and the National Institutes of Health (DK63158). B.F. and S.-W.Q. hold fellowships from University of Oslo.

\(^{2}\) Address correspondence and reprint requests to Dr. Shuo-Wang Qiao, Institute of Immunology, University of Oslo, Rikshospitalet University Hospital, N-0027 Oslo, Norway. E-mail address: s.w.qiao@medisin.uio.no

\(^{3}\) Abbreviations used in this paper: TG2, tissue transglutaminase; B-LCL, EBV-transformed B lymphoblastoid cell line; DC, dendritic cell; HMWF-PT-gliadin, high m.w. fraction of PT-gliadin; Hsp, heat shock protein; MB, *Mycobacterium bovis* PT-gliadin, pepsin trypsin-treated gliadin; TCC, T cell clone.

---

Copyright © 2004 by The American Association of Immunologists, Inc.
FIGURE 1. The 33-mer and its epitopes. The 33-mer (α-gliadin 56–88) contains, in total, six overlapping copies of three DQ2-restricted T cell epitopes. Three glutamine residues (underlined), which we predict to be primarily selected for deamidation by TG2 (10, 11), were converted to glutamic acid in the synthetic deamidated 33-mer.

FIGURE 2. The 33-mer binds to DQ2 with relatively high affinity and with higher affinity than the shorter peptides containing one or two epitopes within the 33-mer. Peptides representing different deamidated gliadin epitopes and two variants of deamidated 33-mer were assessed for DQ2 binding in a cell-free, competitive binding assay at pH 4.9. The peptide PEPOQFQPQFEXPQR represents the DQ2-α-epitope. The peptides 33-mer E-E-E and 33-mer TG2 represent the synthetic deamidated and the TG2-treated 33-mer, respectively. The peptides PQEPELPYPPQELPY and QLPFPQQPFPQ represent DQ2-αII/III and -δ epitopes, respectively.

Ag PROCESSING REQUIREMENTS OF A GLIADIN 33-MER

Dr3/DQ2 homozygous individual (CD114) was cultured in RPMI 1640 with 10% FCS (both from Invitrogen Life Technologies, Carlsbad, CA). The DC were prepared from PBMC of Dr3/DQ2-positive blood donors. Monocytes were positively selected from the PBMC with anti-CD14 mAb-coated MicroBeads (MACS, Miltenyi Biotec, Bergisch Gladbach, Germany) and then cultured in RPMI 1640 with 10% FCS containing 1000 U/ml GM-CSF and 500 U/ml IL-4 (both from R&D Systems, Abingdon, U.K.). On day 6, some DC were matured with 150 ng/ml LPS (Sigma-Aldrich) for 48 h, and the rest were kept immature in the GM-CSF/IL-4 medium. Both immature and mature DC were used as APC on day 8, and both cell sets were >95% CD11c+, as ascertained by flow cytometry. The mature DC expressed CD83 and showed up-regulated expression of CD86 and HLA class II molecules compared with the immature DC.

T cell assays

For use in T cell assays, HMWF-PT gliadin and the 33-mer were preincubated with 200 μg/ml GST-TG2 in PBS with 2 mM CaCl2 for 2 h at 37°C. In glutaraldehyde fixation of the APC, B-LCL or DC were washed with serum-free RPMI 1640 and incubated with 0.05% glutaraldehyde in RPMI 1640 for 90 s at 22°C before 0.2 M glycine were added for an additional 60 s. The cells were then thoroughly washed. Live B-LCL were irradiated (75 Gy). Fifty thousand fixed or live B-LCL or 20,000 fixed or live DC were cocultivated overnight at 37°C in U-bottom, 96-well plates with various concentrations of Ags in RPMI 1640/10% FCS. After the incubation, the APC were washed twice with cold RPMI 1640 to remove unbound Ags before 50,000 gliadin-specific T cells were added to each well. The final part of the T cell assay was performed in RPMI 1640 with 15% heat-inactivated, pooled human serum. The following T cell clones (TCC) were used: TCC387E9, TCC430.1.142 and TCC423.1.3.8. TCC387E9 and TCC430.1.142 both recognize the DQ2-α-epitope (9-mer core region FPQFQPQPELPYPQPQPELPY, and the closely related α-II/III epitope (9-mer core region FPQFQPQPELPYPQPQPELPY). TCC423.1.3.8 recognizes the DQ2-γ-epitope (9-mer core region PQFQSFPEQ). All three TCC are derived from intestinal biopsies of celiac disease patients and are DQ2 restricted (17). T cell proliferation was measured by the uptake of [3H]thymidine (1 μCi/well; Hartmann Analytic, Braunschweig, Germany), which was added 24 h before harvesting. Cells were harvested after 72 h onto glass-fiber filter paper with an automated harvester (Millipore, Hamden, CT), and [3H]thymidine incorporation was measured by liquid scintillation counting (Wallac MicroBeta TriLum 1450; PerkinElmer, Wellesley, MA). Each Ag concentration was studied in triplicate. At least two independent experiments were performed for each assay.

Results

The 33-mer has a relatively high binding affinity to DQ2

Binding of the 33-mer to DQ2 was assessed in a competitive inhibition assay at pH 4.9 using an [125I]-labeled MB 65 kDa Hsp
243–255Y peptide (KPLILIAEDVEGEY) as the indicator peptide (14). Binding affinities, given as IC_{50} values, of some selected peptides representing gliadin-derived T cell epitopes are shown in Fig. 2. The two variants of the deamidated 33-mer had higher binding affinities to DQ2 molecules than other gliadin-derived peptides tested. The IC_{50} value for the 33-mer treated with TG2 was slightly higher than that of the synthetic deamidated 33-mer.

Processing dependence of the 33-mer and other gliadin T cell epitopes

To address whether presentation of the 33-mer requires further processing, we first used live and glutaraldehyde-fixed B-LCL as APC. To benchmark the assay, we used DQ2-\(\gamma\)-I epitope, which has previously been described as being processing dependent when part of partially proteinolyzed and dialyzed gliadin (18). By using pepsin- and trypsin-digested gliadin that was dialyzed against a membrane with an exclusion size of 12–14 kDa (HMWF-PT-gliadin) and the DQ2-\(\gamma\)-I-specific T cell clone TCC423.1.3.8, we reproduced this finding. A 21-mer deamidated peptide containing the DQ2-\(\gamma\)-I epitope (underlined; YQQLQPQPEPQOQSFPFEQERPF) was presented by both live and fixed B-LCL (Fig. 3A). In contrast, HMWF-PT-gliadin was presented to TCC423.1.3.8 by live DQ2-\(\gamma\)-I/III-speciﬁc APC, but not by same cells fixed by glutaraldehyde (Fig. 3B).

Using the same live and fixed B-LCL, a 12-mer peptide containing the DQ2-\(\alpha\)-I epitope (underlined; QLQPFPQPEPYP) was efficiently recognized by the DQ2-\(\alpha\)-I/III-speciﬁc T cell clone TCC430.1.142 (Fig. 4A). The TG2-treated 33-mer, which contains three copies of DQ2-\(\alpha\)-I and -\(\alpha\)III epitopes, was also presented to the same T cell clone equally well by live and fixed B-LCL. The deamidated 33-mer was much more potent than the \(\alpha\) peptide, and this increased relative stimulatory potency was unchanged by using fixed B-LCL. Also, HMWF-PT-gliadin was presented by B-LCL (Fig. 4B), suggesting that even among the higher m.w. material retained by the dialysis membrane there were fragments that did not require further processing. Similar results were obtained with another DQ2-\(\alpha\)-I/III-speciﬁc T cell clone (TCC387.E9) as the readout (data not shown). These results indicate that the presentation of the 33-mer and larger fragments containing the DQ2-\(\alpha\) or DQ2-\(\alpha\)III epitopes does not require processing by B-LCL for effective T cell presentation.

We next repeated some of these experiments with the T cell clone TCC430.1.142 using live and fixed mature and immature DC as APC. The results are shown for the immature DC (Fig. 4, C and D), but the results were comparable with those for the mature DC. The 12-mer DQ2-\(\alpha\) peptide was equally efficiently presented by fixed and live DC. The TG2-treated 33-mer was also effectively presented by fixed DC, but not as efficiently as live DC (Fig. 4C). Fixed DC also presented the HMWF-PT-gliadin, but as with the 33-mer, the live cells were more effective than the fixed cells (Fig. 4D). The increased potency of the 33-mer compared with the 12-mer was also observed with DC as APC (Fig. 4C).

To further assess the molecular sizes of PT-gliadin fragments that are presented by fixed APC, PT-gliadin was subjected to fractionation by gel ﬁltration. Fractions 7 and 8, containing larger molecules than the 33-mer (which elutes in fraction 10 under the same chromatographic conditions; Fig. 5A), were tested in T cell assays using both live and fixed B-LCL. Similar to results obtained with dialyzed PT-gliadin, the DQ2-\(\alpha\)-II/III-speciﬁc T cell clone TCC430.1.142, but not the DQ2-\(\gamma\)-I-specific T cell clone TCC423.1.3.8, recognized the high m.w. fractions 7 and 8 when presented by fixed B-LCL (Fig. 5B). Using live B-LCL, both T cell clones recognized the same fractions, showing that both the DQ2-\(\alpha\)-II and DQ2-\(\gamma\)-I epitopes were present in fractions 7 and 8 (Fig. 5B).

The 33-mer binds DQ2 efﬁciently at neutral pH in peptide binding assays and T cell assay with B-LCL

We next analyzed the pH dependence of binding of the 33-mer to DQ2. The binding to DQ2 molecules puriﬁed from B-LCL was ﬁrst tested, then in another set of experiments binding to ﬁxed APC was tested using T cell proliferation as the readout. In the experiments with puriﬁed DQ2 molecules, the synthetic deamidated 33-mer, the 33-mer deamidated by TG2, and MB 65 kDa Hsp 243–255Y were labeled with \(^{125}\)I and incubated overnight with detergent-solubilized DQ2 at different pH, and binding was assessed in a gel ﬁltration assay. Peptide MB 65 kDa Hsp 243–255Y bound to DQ2 with a maximum of approximately pH 5.5, in accordance with earlier reports (14), whereas the binding of both 33-mer variants was maximal at pH 6.3 (Fig. 6).

In the T cell assay either TG2-treated 33-mer or synthetic 33-mer peptide with three glutamine residues substituted with glutamic acid were coincubated overnight with ﬁxed B-LCL at three different pH values. The APC were then thoroughly washed to remove unbound peptides and pH-adjusting buffers. Thereafter, the DQ2-\(\alpha\)/III-reactive T cell clone TCC430.1.142 was added to cell culture medium at pH 7.3 and cultured in a standard 3-day T cell proliferation assay. The T cell responses to both deamidated 33-mer variants were higher when APC and 33-mer coinubation was performed at pH 6.3 compared with those at pH 4.9 and pH 7.2 (Fig. 7).

**FIGURE 3.** The DQ2-\(\gamma\)-I epitope is processing dependent when part of the HMWF of pepsin/trypsin-treated gliadin. The processing requirements of Ags containing the DQ2-\(\gamma\)-I epitope were assessed in a T cell assay with T cell clone TCC423.1.3.8 using either live APC (■ and ▲) or glutaraldehyde-fixed APC (□ and △). The DQ2-\(\gamma\) peptide YQQLQPQPEPQOQSFPFEQERPF (■ and □) can be presented by both live and ﬁxed APC (A). HMWF-PT-gliadin (▲ and △) can only be presented by live APC (B). Error bars indicate the observed range within triplicate determinations.
Discussion

The 33-mer (LQLQPFPQHPQPQLPYPQPQLPYPQPQPF, H9251 2–gliadin 56–88) is produced by normal gastrointestinal digestion of recombinant H92512–gliadin. It is extremely resistant to proteolytic degradation, contains six partly overlapping copies of three DQ2-restricted T cell epitopes, and is superstimulatory for T cells (8). Understanding how this peptide binds to DQ2 and how it is handled by APC for presentation to T cells is thus particularly instructive for the learning about the disease mechanisms of celiac disease. In this study we confirm the initial observations on the stimulatory potency of the 33-mer with live APC and show that the 33-mer is presented efficiently by fixed APC. Notably, this increased stimulatory potency is also retained after fixation of the APC.

Extracellular Ags can be presented by APC in either of two ways. The classical Ag processing and presentation pathway includes Ag uptake into the endosomal compartment, proteolytic fragmentation in the lysosomal compartments, and binding of the resultant peptide fragments to MHC class II molecules. Most proteins are processing dependent and presented via this pathway. The alternative pathway for Ag binding is the direct binding of Ags to HLA class II molecules on the cell surface, which does not require Ag processing by APC. In this study, we investigated the processing requirements of Ags containing the DQ2-restricted T cell epitope. Two types of APC sources, either EBV-transformed B cells (B-LCL; A and B), or immature monocyte-derived DC (C and D) were tested as live (■ and □) or glutaraldehyde fixed cells (■ and △) in T cell assays using the T cell clone TCC430.1.142. The 12-mer DQ2-restricted 33-mer (■ and □) (A and C) and TG2-treated 33-mer (△ and ○) (A and C) and TG2-treated HMWF-PT-gliadin (△ and ○) were presented by both live and fixed APC of both types. The 33-mer was more potent for T cell stimulation than the DQ2-restricted 33-mer with all types of APC. Error bars indicate the observed range within triplicate determinations.

**FIGURE 4.** Processing requirements of Ags containing the DQ2-restricted T cell epitope. Two types of APC sources, either EBV-transformed B cells (B-LCL; A and B), or immature monocyte-derived DC (C and D) were tested as live (■ and □) or glutaraldehyde fixed cells (□ and △) in T cell assays using the T cell clone TCC430.1.142. The 12-mer DQ2-restricted 33-mer (■ and □) (A and C) and TG2-treated 33-mer (△ and ○) (A and C) and TG2-treated HMWF-PT-gliadin (△ and ○) were presented by both live and fixed APC of both types. The 33-mer was more potent for T cell stimulation than the DQ2-restricted 33-mer with all types of APC. Error bars indicate the observed range within triplicate determinations.

**FIGURE 5.** Fragments of peptic/tryptic digest of gliadin even longer than the 33-mer do not require processing by APC for T cell recognition. Pepsin/trypsin-treated gliadin (500 μg) and 33-mer (60 μg) were subjected to FPLC gel filtration (Superdex Peptide 10/30 column; exclusion size, 20 kDa) and monitored by UV absorbance at OD 280 (A). The 33-mer was almost exclusively eluted in fraction 10. Materials from fractions 7 and 8 were tested for T cell recognition with either live or fixed APC (B). Both fraction 7 (□) and fraction 8 (■) were recognized by the T cell clones specific for DQ2-αII/III (TCC430.1.142) and DQ2-γ1 (TCC423.1.3.8) when presented by live B-LCL. Using glutaraldehyde-fixed B-LCL, both fractions were only recognized by the DQ2-αII/III-specific T cell clone, not the DQ2-γ1-specific T cell clone. Error bars indicate the observed range within triplicate determinations.

**FIGURE 6.** The 33-mer binds HLA-DQ2 most efficiently at approximately pH 6.3 in cell-free peptide binding assay. The binding efficiency of 125I-labeled synthetic deamidated 33-mer (□), TG2-treated 33-mer (△), and the high affinity binder MB 65 kDa Hsp 243–255Y (●) to purified detergent-solubilized DQ2 molecules were assessed in a direct peptide binding assay at various pH. For each peptide, the binding is presented as a percentage of the maximum binding of this peptide. Maximum binding was 14.3% for the synthetic deamidated 33-mer, 7.2% for the TG2-treated 33-mer, and 10.7% for MB 65 kDa Hsp 243–255Y. Error bars indicate the observed range. Three vertical lines were drawn at pH 4.9, 6.3, and 7.2.
polypeptides to surface-expressed MHC class II molecules, without being internalized and processed. Shorter peptides are usually able to use this presentation pathway, but even some longer peptides of 30–39 aa (19, 20), intact proteins (i.e., fibrinogen) (21), and denatured proteins (i.e., bovine albumin, hen egg lysozyme, OVA, and human transferrin) (22) have been shown to bind to the appropriate MHC class II molecules in the absence of processing. Our observations that the 33-mer α-gliadin peptide can bind directly to DQ2 and that both 33-mer and pepsin, trypsin-generated fragments >10 kDa, can be presented by fixed APC that had been incubated with either the deamidated 33-mer (A) or the TG2-treated 33-mer (B) at three different pH (solid line, 4.9; dotted line, 6.3; broken line, 7.2). Error bars indicate the observed range within triplicate determinations.

FIGURE 7. The 33-mer is most efficiently presented to T cells when incubated with fixed APC at pH 6.3 compared with pH 4.9 or 7.2. T cell proliferation of the T cell clone TCC430.1.142 was measured after stimulation with fixed and washed APC that had been incubated with either the deamidated 33-mer (A) or the TG2-treated 33-mer (B) at three different pH (solid line, 4.9; dotted line, 6.3; broken line, 7.2). Error bars indicate the observed range within triplicate determinations.

This suggests that at least part of the effect is related directly to HLA binding and does not involve signal transduction in the APC, which has been shown to be important for the superstimulatory activity of artificially multimerized T cell epitopes (23). Increasing antigenicity as a function of peptide length has also been reported for a cytochrome c epitope (24). T cell recognition of this epitope was independent of processing, and the antigenicity was continuously improved by extension of the core peptide region. A 23-mer peptide was >30 times more potent than the 12-mer core peptide. Moreover, a hybrid peptide of 51 residues containing the cytochrome c epitope and a T cell epitope derived from tetanus toxoid not only required no processing, but was 1 log more efficient than the cytochrome c of less than half its size. This length-dependent antigenicity of the cytochrome c peptides was also observed using lipid membrane-associated I-Ek, suggesting that this phenomenon is related to MHC binding per se. Our results with the 33-mer, including the binding data, are analogous to these observations. They raise the possibility that long gluten protein fragments surviving gastrointestinal digestion have the potential to be particularly immunogenic as a function of their length or because they can act multivalently for binding to DQ2. The identification of additional gluten T cell epitopes in celiac disease should take this into account.

Among the peptides eluted from DQ2 molecules of B-LCL, CLIP peptides are remarkably abundant (25–28). This may relate to binding of an unusual register of CLIP peptides in addition to the conventional register (25–26) as well as a potentially low eficiency of HLA-DM to unload CLIP peptides from DQ2. At any rate, cell surface DQ2 with abundant CLIP peptides available for exchange reactions should be particularly fit for cell surface binding of peptides. This may be one of the reasons why DQ2 predisposes to celiac disease. Not only can DQ2 bind the register-constraining, proline-rich gluten peptides with high affinities by accommodating glutamate residues in the P4, P6, or P7 pocket (29), but it can also directly bind gluten peptides that are produced by the gastrointestinal enzymatic digestion. The 33-mer is particularly proline rich and adopts type II polyproline helical conformation in solution. The fact that the free 33-mer has already adopted the required conformation for MHC class II binding may promote its binding to cell surface DQ2 by exchange with CLIP or other prebound peptides without the need for HLA-DM.

A limited set of peptides with high affinity binding to DQ2 has been found to exhibit a pH binding optimum at ~5 (14). Interestingly, the 33-mer has a pH optimum closer to what is found in the extracellular milieu, which is relevant for binding to DQ2 at the cell surface. At this point, we do not know the factors involved in this peptide-dependent pH effect on binding. It could relate to variable protonation of the peptides. The fact that the 33-mer adopts a type II polyproline helical conformation in solution may also be relevant.

The requirement for processing of food Ags by APC in the gut may be a special case, because these Ags are preprocessed by gastrointestinal digestion. Although most dietary proteins are broken down to amino acids or di- or tripeptides by the consecutive proteolytic actions of gastric, pancreatic, and small intestine brush-border membrane enzymes (30), significant amounts of the 33-mer remain intact after the digestion of α5-gliadin by all these enzymes (8). Interestingly, a corresponding 12-mer peptide, QLQPPFQQLPY (α5-gliadin 57-68), containing the native sequence of the α1 epitope, is produced by similar proteolytic digestion of α5-gliadin (2). T cells that become activated in intestinal biopsies by gluten stimulation in vitro are mainly CD4+ T cells located in the lamina propria (1, 13). The gluten peptides will thus have to access DQ2-positive APCs in this subepithelial compartment. Although
enterocytes have been suggested to play a role in gliadin uptake and presentation in celiac disease (31), these cells generally lack expression of HLA-DQ molecules (32), and it therefore seems unlikely that DQ2-binding gliadin peptides should associate with HLA molecules of epithelial cells. Recently, intestinal transport and degradation of the 33-mer and other gliadin peptides were studied by mounting duodenal biopsies in Ussing chambers (33). After intestinal transport, gliadin peptides were found to be fully digested by enterocytes in controls and celiac patients in remission and to a somewhat slighter degree in patients with active celiac disease. Of note, however, selective uptake of luminal peptides by DC would not be measured in this system. Interestingly, DC express tight junction proteins and penetrate gut epithelial monolayers; they can thereby sample Ags directly from the intestinal lumen (34). DC also express vast amounts of TG2 (35). Our observation speaks to the possibility that luminal 33-mer and other gluten peptides produced by the gastrointestinal digestion can be deamidated by TG2 expressed in the enterocyte brush border or by DC and then be picked up by DC, partly by direct binding to DQ2, for later presentation to T cells in the lamina propria.

In summary, we demonstrate that a 33-mer of α-gliadin that is the end product of normal gastrointestinal proteolysis can be presented to T cells without further processing by APCs. The binding of the 33-mer does not show the pH 5 optimum found for other DQ2 ligands (14), but, rather, has an optimum around pH 6, closer to the pH 7 optimum found for other HLA-DQ ligands (14). DC also express vast amounts of TG2 (35). Our observation speaks to the possibility that luminal 33-mer and other gluten peptides produced by the gastrointestinal digestion can be deamidated by TG2 expressed in the enterocyte brush border or by DC and then be picked up by DC, partly by direct binding to DQ2, for later presentation to T cells in the lamina propria.

References